McMichael A J, Callan M, Appay V, Hanke T, Ogg G, Rowland-Jones S
MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29;355(1400):1007-11. doi: 10.1098/rstb.2000.0637.
Recent advances in measuring T-cell responses to viruses have led to new insights into how these T cells respond. In the acute infection there are massive CD8+ T-cell responses to both Epstein-Barr virus (EBV) and to human immunodeficiency virus (HIV). Many of these T cells are effector cells and only a minority appear to be capable of maintaining immunological memory. In persistent virus infections, high levels of antigen-specific effector cells persist. If virus does not persist, the effectors fade in number but memory is maintained and is primed to react rapidly to a new challenge. A vaccine that stimulates only T-cell responses may protect when these memory cells respond rapidly enough to generate high numbers of effectors before the infecting virus becomes established.
测量T细胞对病毒反应的最新进展,为了解这些T细胞的反应方式带来了新的见解。在急性感染中,针对EB病毒(EBV)和人类免疫缺陷病毒(HIV)都有大量的CD8+T细胞反应。这些T细胞中的许多都是效应细胞,只有少数似乎能够维持免疫记忆。在持续性病毒感染中,高水平的抗原特异性效应细胞持续存在。如果病毒不再持续存在,效应细胞数量会减少,但记忆会得以维持,并准备好对新的挑战迅速做出反应。当这些记忆细胞反应足够迅速,在感染病毒定植之前产生大量效应细胞时,仅刺激T细胞反应的疫苗可能会起到保护作用。